Pelareorep in Gastrointestinal Cancers

For the growing number of patients with gastrointestinal cancers, effective therapies that improve treatment outcomes and meaningfully extend survival are limited.¹ Indeed, fewer than 12% of patients receiving the current standard-of-care for pancreatic cancer survive 5 years beyond their diagnosis.² To address this profoundly unmet need, Oncolytics is conducting the GOBLET trial to examine the potential of pelareorep and the checkpoint inhibitor atezolizumab in addition to standard-of-care therapy, where appropriate, for gastrointestinal cancers, including advanced/metastatic pancreatic cancer. The combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab received FDA Fast Track designation for the treatment of advanced/metastatic pancreatic cancer.

As a result of the Fast Track designation and the promising data reported to date, Oncolytics is planning an adaptive Phase 3 program and intends to manage it directly within its Clinical Group and a contract research organization (CRO) with the goal of enrolling the first patient in mid-2024.